- Home
- PDO vs NKTR Comparison
PDO vs NKTR Comparison
Compare PDO & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PDO | NKTR |
|---|---|---|
| Founded | 2020 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | PDO | NKTR |
|---|---|---|
| Price | $12.36 | $69.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $146.67 |
| AVG Volume (30 Days) | ★ 929.5K | 509.5K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 11.80% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $307,711,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $12.36 | $33.40 |
| 52 Week High | $14.25 | $109.00 |
Technical Indicators
Market Signals| Indicator | PDO | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 44.65 |
| Support Level | $12.40 | $70.24 |
| Resistance Level | $13.20 | $76.49 |
| Average True Range (ATR) | 0.16 | 2.88 |
| MACD | 0.01 | -0.31 |
| Stochastic Oscillator | 32.63 | 15.34 |
Price Performance
Historical ComparisonAbout PDO PIMCO Dynamic Income Opportunities Fund of Beneficial Interest
PIMCO Dynamic Income Opportunities Fund is a closed-end management investment company. The fund's primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.